Paradoxical effect of cortistatin treatment and its deficiency on experimental autoimmune encephalomyelitis

Journal of Immunology

Volumn 191, Issue 5, 2013, Pages 2144-2154

  Souza Moreira, Luciana ^a   Morell, Maria ^a   Delgado Maroto, Virginia ^a   Pedreño, Marta ^a   Martinez Escudero, Laura ^a,b   Caro, Marta ^a   O'Valle, Francisco ^c   Luque, Raul ^d   Gallo, Milagros ^b   De Lecea, Luis ^e   Castaño, Justo P ^d   Gonzalez Rey, Elena ^a,f  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c Medical School of Granada   (Spain)

^d Universidad de Cordoba   (Spain)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CORTISTATIN; GLUCOCORTICOID;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTHRITIS; ARTICLE; AXONAL INJURY; COLITIS; CONTROLLED STUDY; DEMYELINATION; DISEASE RESISTANCE; DOWN REGULATION; DRUG EFFECT; FEMALE; IMMUNOREGULATION; INFLAMMATORY INFILTRATE; MOUSE; NERVE FIBER REGENERATION; NEUROPROTECTION; NEWBORN; NONHUMAN; PAW EDEMA; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPINAL CORD; SYSTEMIC THERAPY; TH1 CELL; TH17 CELL;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROPEPTIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPINAL CORD; T-LYMPHOCYTES;

EID: 84883369505     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300384     Document Type: Article

References (43)

1. Steinman, L. 1996. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85: 299-302.
2. Steinman, L. 1999. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron 24: 511-514.
3. Owens, T. 2003. The enigma of multiple sclerosis: inflammation and neurodegeneration cause heterogeneous dysfunction and damage. Curr. Opin. Neurol. 16: 259-265.
4. + regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199: 971-979.
5. de Lecea, L., J. R. Criado, O. Prospero-Garcia, K. M. Gautvik, P. Schweitzer, P. E. Danielson, C. L. Dunlop, G. R. Siggins, S. J. Henriksen, and J. G. Sutcliffe. 1996. A cortical neuropeptide with neuronal depressant and sleep-modulating properties. Nature 381: 242-245.
6. Gahete, M. D., M. Durán-Prado, R. M. Luque, A. J. Martínez-Fuentes, R. Vázquez-Martínez, M. M. Malagón, and J. P. Castaño. 2008. Are somatostatin and cortistatin two siblings in regulating endocrine secretions? In vitro work ahead. Mol. Cell. Endocrinol. 286: 128-134.
7. Spier, A. D., and L. de Lecea. 2000. Cortistatin: a member of the somatostatin neuropeptide family with distinct physiological functions. Brain Res. Brain Res. Rev. 33: 228-241.
8. Gonzalez-Rey, E., A. Chorny, G. Robledo, and M. Delgado. 2006. Cortistatin, a new antiinflammatory peptide with therapeutic effect on lethal endotoxemia. J. Exp. Med. 203: 563-571.
9. Gonzalez-Rey, E., N. Varela, A. F. Sheibanie, A. Chorny, D. Ganea, and M. Delgado. 2006b. Cortistatin, an antiinflammatory peptide with therapeutic action in inflammatory bowel disease. Proc. Natl. Acad. Sci. USA 103: 4228-4233.
10. Gonzalez-Rey, E., A. Chorny, R. G. Del Moral, N. Varela, and M. Delgado. 2007. Therapeutic effect of cortistatin on experimental arthritis by downregulating inflammatory and Th1 responses. Ann. Rheum. Dis. 66: 582-588.
11. Dalm, V. A., P. M. van Hagen, P. M. van Koetsveld, A. W. Langerak, A. J. van der Lely, S. W. Lamberts, and L. J. Hofland. 2003. Cortistatin rather than somatostatin as a potential endogenous ligand for somatostatin receptors in the human immune system. J. Clin. Endocrinol. Metab. 88: 270-276.
12. Córdoba-Chacón, J., M. D. Gahete, A. I. Pozo-Salas, A. J. Martínez-Fuentes, L. de Lecea, F. Gracia-Navarro, R. D. Kineman, J. P. Castaño, and R. M. Luque. 2011. Cortistatin is not a somatostatin analogue but stimulates prolactin release and inhibits GH and ACTH in a gender-dependent fashion: potential role of ghrelin. Endocrinology 152: 4800-4812.
13. Kluver, H., and E. Barrera. 1953. A method for the combined staining of cells and fibers in the nervous system. J. Neuropathol. Exp. Neurol. 12: 400-403.
14. Mecha, M., P. M. Iñigo, L. Mestre, M. Hernangómez, J. Borrell, and C. Guaza. 2011. An easy and fast way to obtain a high number of glial cells from rat cerebral tissue: A beginners approach. Protocol Exchange. doi: 10.1038/protex. 2011.2188
15. Morell, M., L. Souza-Moreira, M. Caro, F. O'Valle, I. Forte-Lago, L. de Lecea, E. Gonzalez-Rey, and M. Delgado. 2013. Analgesic effect of the neuropeptide cortistatin in murine models of arthritic inflammatory pain. Arthritis Rheum. 65: 1390-1401.
16. Bale, T. L., A. Contarino, G. W. Smith, R. Chan, L. H. Gold, P. E. Sawchenko, G. F. Koob, W. W. Vale, and K. F. Lee. 2000. Mice deficient for corticotropinreleasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat. Genet. 24: 410-414.
17. Sacks, D. L., S. Hieny, and A. Sher. 1985. Identification of cell surface carbohydrate and antigenic changes between noninfective and infective developmental stages of Leishmania major promastigotes. J. Immunol. 135: 564-569.
18. von Stebut, E., Y. Belkaid, B. V. Nguyen, M. Cushing, D. L. Sacks, and M. C. Udey. 2000. Leishmania major-infected murine langerhans cell-like dendritic cells from susceptible mice release IL-12 after infection and vaccinate against experimental cutaneous Leishmaniasis. Eur. J. Immunol. 30: 3498-3506.
19. Baxter, A. G. 2007. The origin and application of experimental autoimmune encephalomyelitis. Nat. Rev. Immunol. 7: 904-912.
20. Jäger, A., V. Dardalhon, R. A. Sobel, E. Bettelli, and V. K. Kuchroo. 2009. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J. Immunol. 183: 7169-7177.
21. Codarri, L. G., G. Gyülvészi, V. Tosevski, L. Hesske, A. Fontana, L. Magnenat, T. Suter, and B. Becher. 2011. RORgt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 12: 560-567.
22. Kohm, A. P., P. A. Carpentier, H. A. Anger, and S. D. Miller. 2002. Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol. 169: 4712-4716.
23. Bynoe, M. S., J. T. Evans, C. Viret, and C. A. Janeway, Jr. 2003. Epicutaneous immunization with autoantigenic peptides induces T suppressor cells that prevent experimental allergic encephalomyelitis. Immunity 19: 317-328.
24. Linker, R. A., D. H. Lee, S. Demir, S. Wiese, N. Kruse, I. Siglienti, E. Gerhardt, H. Neumann, M. Sendtner, F. Lühder, and R. Gold. 2010. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain 133: 2248-2263.
25. Lewin, G. R., and Y. A. Barde. 1996. Physiology of the neurotrophins. Annu. Rev. Neurosci. 19: 289-317.
26. Braitch, M., K. Kawabe, M. Nyirenda, L. J. Gilles, R. A. Robins, B. Gran, S. Murphy, L. Showe, and C. S. Constantinescu. 2010. Expression of activitydependent neuroprotective protein in the immune system: possible functions and relevance to multiple sclerosis. Neuroimmunomodulation 17: 120-125.
27. Sternberg, E. M. 2006. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat. Rev. Immunol. 6: 318-328.
28. Komiyama, Y., S. Nakae, T. Matsuki, A. Nambu, H. Ishigame, S. Kakuta, K. Sudo, and Y. Iwakura. 2006. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 177: 566-573.
29. Reboldi, A., C. Coisne, D. Baumjohann, F. Benvenuto, D. Bottinelli, S. Lira, A. Uccelli, A. Lanzavecchia, B. Engelhardt, and F. Sallusto. 2009. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat. Immunol. 10: 514-523.
30. Wang, J., R. Zhao, F. Zhang, J. Li, B. Huo, Y. Cao, and K. Dou. 2008. Control of allograft rejection in mice by applying a novel neuropeptide, cortistatin. Adv. Ther. 25: 1331-1341.
31. Gonzalez-Rey, E., A. Chorny, and M. Delgado. 2007. Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat. Rev. Immunol. 7: 52-63.
32. Groux, H., and F. Cottrez. 2003. The complex role of interleukin-10 in autoimmunity. J. Autoimmun. 20: 281-285.
33. Carrasco, E., C. Hernández, I. de Torres, J. Farrés, and R. Simó. 2008. Lowered cortistatin expression is an early event in the human diabetic retina and is associated with apoptosis and glial activation. Mol. Vis. 14: 1496-1502.
34. Abad, C., Y. V. Tan, R. Lopez, H. Nobuta, H. Dong, P. Phan, J. M. Feng, A. T. Campagnoni, and J. A. Waschek. 2010. Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 107: 19555-19560.
35. Giordano, R., A. Picu, L. Bonelli, F. Broglio, F. Prodam, S. Grottoli, G. Muccioli, E. Ghigo, and E. Arvat. 2007. The activation of somatostatinergic receptors by either somatostatin-14 or cortistatin-17 often inhibits ACTH hypersecretion in patients with Cushing's disease. Eur. J. Endocrinol. 157: 393-398.
36. Tringali, G., M. C. Greco, L. Lisi, G. Pozzoli, and P. Navarra. 2012. Cortistatin modulates the expression and release of corticotrophin releasing hormone in rat brain. Comparison with somatostatin and octreotide. Peptides 34: 353-359.
37. Pavlov, V. A., and K. J. Tracey. 2012. The vagus nerve and the inflammatory reflex - linking immunity and metabolism. Nat. Rev. Endocrinol. 8: 743-754.
38. Shi, F. D., W. H. Piao, Y. P. Kuo, D. I. Campagnolo, T. L. Vollmer, and R. J. Lukas. 2009. Nicotinic attenuation of central nervous system inflammation and autoimmunity. J. Immunol. 182: 1730-1739.
39. Cosentino, M., M. Zaffaroni, M. Giorelli, F. Marino, M. Ferrari, R. Bombelli, E. Rasini, M. Trojano, S. Lecchini, P. Livrea, et al. 2004. Adrenergic mechanisms in multiple sclerosis: the neuro-immune connection? Trends Pharmacol. Sci. 25: 350-351, author reply 351-352.
40. Brosnan, C. F., E. A. Goldmuntz, W. Cammer, S. M. Factor, B. R. Bloom, and W. T. Norton. 1985. Prazosin, an alpha 1-adrenergic receptor antagonist, suppresses experimental autoimmune encephalomyelitis in the Lewis rat. Proc. Natl. Acad. Sci. USA 82: 5915-5919.
41. Souza-Moreira, L., V. Delgado-Maroto, M. Morell, F. O'Valle, R. G. Del Moral, and E. Gonzalez-Rey. 2013. Therapeutic effect of ghrelin in experimental autoimmune encephalomyelitis by inhibiting antigen-specific Th1/Th17 responses and inducing regulatory T cells. Brain Behav. Immun. 30: 54-60.
42. Chuang, J. C., M. Perello, I. Sakata, S. Osborne-Lawrence, J. M. Savitt, M. Lutter, and J. M. Zigman. 2011. Ghrelin mediates stress-induced food-reward behavior in mice. J. Clin. Invest. 121: 2684-2692.
43. Asakawa, A., A. Inui, T. Kaga, H. Yuzuriha, T. Nagata, M. Fujimiya, G. Katsuura, S. Makino, M. A. Fujino, and M. Kasuga. 2001. A role of ghrelin in neuroendocrine and behavioral responses to stress in mice. Neuroendocrinology 74: 143-147.